Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Oral body temperature and cerebrospinal fluid pTau181 in older adults at increased risk of Alzheimer's disease.

Neurobiology of aging·2026
Same author

Cardiovascular risk and hippocampal-cognitive coupling in Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.

medRxiv : the preprint server for health sciences·2026
Same author

Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributions.

Nature communications·2026
Same author

Longitudinal association between sleep and Alzheimer's pathology.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Sex Differences in P-Tau217, Tau Aggregation, and Cognitive Decline.

JAMA neurology·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Sylvia Villeneuve1

  • 1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Montréal, QC, Canada; McGill University, Montreal, QC, Canada; StoP-AD Centre, Douglas Mental Health Institute Research Centre, Montreal, QC, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

在PET扫描中,具有粉样蛋白和蛋白病理的认知正常个体总是会进展到轻度认知障碍或痴呆症. 长时间的随访也显示了那些只有粉样蛋白病理的人的进展增加.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物研究 生物标志物研究
  • 阿尔茨海默氏症疾病的诊断方法

背景情况:

  • 关于将患有阿尔茨海默氏症病理的认知无障碍个体归类为患有阿尔茨海默氏症,存在争论.
  • 之前的研究表明,大约一半的粉样蛋白阳性和阳性 (A+T+) 认知正常的个体在3.5年内发展为轻度认知障碍 (MCI) 或痴呆症.
  • 只有粉样蛋白病理 (A+T-) 的个体与没有病理 (A-T-) 的个体相比,没有增加MCI或痴呆的风险.

研究的目的:

  • 评估粉样蛋白和定子发射断层扫描 (PET) 生物标志物的预后价值,以识别在6年时间内会患上MCI的认知不受损的个体.
  • 探索用于检测粉样蛋白和PET阳性的新方法,这些方法可能比传统方法更敏感.
  • 通过确定最有可能从早期干预中受益的个体来告知临床试验招生.

主要方法:

  • 在PREVENT-AD研究中对认知正常参与者的长度随访.
  • 评估认知状态和进展到MCI或痴呆症.
  • 使用粉样蛋白和PET生物标志物 (A+T+,A+T-,A-T-) 来对参与者进行分类.
  • 在额外的2.4年随访后,对更新的认知状态的分析.

主要成果:

  • 100%的A+T+参与者进展为MCI或痴呆症,随着长时间的随访.
  • 在A+T-组的进展率显著增加,从9.09%增加到42.42%,随着长时间的随访.
  • 这些发现提供了强有力的证据,即粉样蛋白和病理结合预测了未受损的个体的认知衰退.

结论:

  • 如果没有治疗,PET检测到的粉样斑块和陶聚合物的认知正常个体肯定会发展出认知障碍.
  • A+T-生物标志物组的预后较差,随着长时间的随访,这表明潜在的病理并不总是可以通过当前的PET值来检测到的.
  • 准确的生物标志物评估对于早期诊断,预后和阿尔茨海默病研究中有效的临床试验设计至关重要.